Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 13, Issue 594, Pages eabd1346
Publisher
American Association for the Advancement of Science (AAAS)
Online
2021-05-20
DOI
10.1126/scitranslmed.abd1346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dendritic cells, the T cell-inflamed tumor microenvironment and immunotherapy treatment response
- (2020) Christopher S. Garris et al. CLINICAL CANCER RESEARCH
- A conserved dendritic-cell regulatory program limits antitumour immunity
- (2020) Barbara Maier et al. NATURE
- Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
- (2020) Alexander H. Morrison et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity
- (2020) Stephen T. Ferris et al. NATURE
- Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling
- (2020) Anthony C. Antonelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- BATF3 programs CD8+ T cell memory
- (2020) Marco A. Ataide et al. NATURE IMMUNOLOGY
- First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
- (2019) Sandra M. M. Irenaeus et al. INTERNATIONAL JOURNAL OF CANCER
- A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity
- (2019) Hayley S. Ma et al. Cancer Immunology Research
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
- (2019) Laura M. McLane et al. Annual Review of Immunology
- Management of metastatic bladder cancer
- (2019) Rosa Nadal et al. CANCER TREATMENT REVIEWS
- In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors
- (2019) Danny N. Khalil et al. JOURNAL OF CLINICAL INVESTIGATION
- CD40 Agonist Antibodies in Cancer Immunotherapy
- (2019) Robert H. Vonderheide Annual Review of Medicine
- Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy
- (2018) Ryoichi Saito et al. CANCER RESEARCH
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Mechanisms of BCG immunotherapy and its outlook for bladder cancer
- (2018) Caroline Pettenati et al. Nature Reviews Urology
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
- (2018) David A. Knorr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review
- (2017) Manmeet Saluja et al. INTERNATIONAL JOURNAL OF UROLOGY
- BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
- (2017) Ashish M. Kamat et al. Nature Reviews Urology
- Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
- (2017) Manisha Singh et al. Nature Communications
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
- (2016) Edward W. Roberts et al. CANCER CELL
- Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
- (2016) Shin Foong Ngiow et al. CANCER RESEARCH
- Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
- (2016) Gregory L. Beatty et al. Expert Review of Anticancer Therapy
- Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species
- (2016) Martin Guilliams et al. IMMUNITY
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
- (2016) Katelyn T. Byrne et al. Cell Reports
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
- (2014) Miranda L. Broz et al. CANCER CELL
- Type I and type II Fc receptors regulate innate and adaptive immunity
- (2014) Andrew Pincetic et al. NATURE IMMUNOLOGY
- BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model
- (2013) Cyrill A. Rentsch et al. PLoS One
- Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop
- (2013) Jonathan P. Jarow et al. UROLOGY
- Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
- (2013) F. Chowdhury et al. Cancer Immunology Research
- A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies
- (2012) Fubin Li et al. CELL CYCLE
- Mouse model recapitulating human Fc receptor structural and functional diversity
- (2012) P. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
- (2012) C. Biot et al. Science Translational Medicine
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity
- (2008) K. Hildner et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started